INTRA-CELLULAR THERAPIES INC (ITCI)       53.54  -0.68 (-1.25%)

53.54  -0.68 (-1.25%)

US46116X1019 - Common Stock

Buy % Consensus

Analysts have set a mean price target of 69.12. This target is 29.11% above the current price.
ITCI was analyzed by 19 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ITCI.
In the previous month the buy percentage consensus was at a similar level.
ITCI was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 53.5449.4968.3469.1294.50 - -7.56% 27.64% 29.11% 76.50%

Up and Down Grades

Date Firm Action Rating
2022-08-22 Goldman Sachs Downgrade Buy -> Neutral
2022-08-11 Mizuho Maintains Buy
2022-08-10 Needham Maintains Buy
2022-08-10 RBC Capital Maintains Outperform
2022-07-07 Mizuho Initiate Buy
2022-06-14 UBS Initiate Buy
2022-04-22 Piper Sandler Initiate Neutral
2022-04-21 SVB Leerink Maintains Outperform
2022-03-02 SVB Leerink Maintains Outperform
2022-02-25 Needham Maintains Buy
2022-02-16 Goldman Sachs Initiate Buy
2021-12-21 RBC Capital Maintains Outperform
2021-12-20 Needham Maintains Buy
2021-12-20 SVB Leerink Maintains Outperform
2021-11-10 RBC Capital Maintains Outperform
2021-10-19 RBC Capital Maintains Outperform
2021-09-23 Needham Initiate Buy
2021-09-20 Jefferies Maintains Buy

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA